Sanofi
Sanofi's deal with Abbott will be focusing on the diabetes space, while its deal with Happify will be looking at treating MS symptoms using a digital therapeutic.
Panelists at MassBio's Digital Health Impact event yesterday talk the pros and cons of the West Coast's tech culture and the East Coast's clinical tradition.
Pharma companies also continued to explore the promises of digital therapeutics.
At BIO 2019, Sanofi's chief medical and digital officer advised fellow pharma leaders on embracing new technologies and preparing for the challenges they'll bring.
The pharmas will be employing Verily's Project Baseline platform to streamline recruitment and data collection during clinical research.
Sanofi execs Ruchita Sinha and Christina Koutoudis share the company’s thoughts about digital technology, innovation and pharma's role and future.
Also: The pharma industry continues to use digital technologies for R&D and diabetes management.
The SurroSense Rx system will be available to Onduo's members in 2019.
MobiHealthNews tracked investments, pilots, partnerships and app launches from major pharma companies during the quarter.
The startup is also working with other pharma companies and plans to expand its relationship with Sanofi.